Future of Personalized Medicine in Non-Small-Cell Lung Cancer

V. Hirsh

doi:10.3747/co.19.1049

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Editorial

1 June 2012

Future of Personalized Medicine in Non-Small-Cell Lung Cancer

Department of Oncology, McGill University Health Centre, Montreal, QC, Canada

Curr. Oncol.2012, 19(s1), 86;https://doi.org/10.3747/co.19.1049

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

The remarkable progress we are witnessing in the understanding of the molecular biology and signalling pathways of non-small-cell lung cancer (NSCLC) cells has resulted in ErbB-targeted therapies and many other targeted agents, especially Alk inhibitors, now in clinical trials [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials

Saponins Isolated from Asparagus Induce Apoptosis in Human Hepatoma Cell Line HepG2 Through a Mitochondrial-Mediated Pathway